|Articles|February 1, 2003
Accutane Draws Crowd
Dermatologists aren't the only ones who see the virtues of Accutane (isotretinoin).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
2
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
5














